Profile data is unavailable for this security.
About the company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
- Revenue in USD (TTM)187.23m
- Net income in USD-43.03m
- Incorporated2007
- Employees167.00
- LocationAkebia Therapeutics Inc245 First StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 871-2098
- Fax+1 (617) 871-2099
- Websitehttps://akebia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agenus Inc | 161.42m | -239.61m | 228.05m | 389.00 | -- | -- | -- | 1.41 | -12.68 | -12.68 | 8.49 | -9.59 | 0.4823 | -- | 170.54 | 414,951.20 | -74.69 | -55.02 | -242.74 | -115.31 | 99.43 | -- | -154.88 | -102.92 | -- | -1.25 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 233.97m | 76.00 | -- | 13.57 | -- | 540.30 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 234.65m | 116.00 | -- | -- | -- | 6.92 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 234.69m | 10.00 | -- | 2.07 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 236.83m | 100.00 | -- | 8.53 | -- | 2.82 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 240.00m | 9.00 | -- | 2.12 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 241.04m | 167.00 | -- | -- | -- | 1.29 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 243.22m | 249.00 | -- | -- | -- | 0.8057 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Generation Bio Co | 9.96m | -169.06m | 243.50m | 174.00 | -- | 1.84 | -- | 24.44 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 244.34m | 51.00 | -- | 1.33 | -- | 15.13 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 246.75m | 274.00 | -- | 1.19 | -- | 3.47 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 249.14m | 57.00 | -- | 0.9243 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Chromadex Corp | 83.17m | -3.53m | 249.28m | 106.00 | -- | 8.57 | -- | 3.00 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 249.37m | 152.00 | -- | 1.10 | -- | 182.02 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 252.16m | 50.00 | -- | 1.89 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Akebia Therapeutics Inc's reporting currency: US Dollar USD
15.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.17m | 3.90% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 5.31m | 2.54% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 3.65m | 1.74% |
| Millennium Management LLCas of 31 Mar 2024 | 3.27m | 1.56% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.47m | 1.18% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 2.26m | 1.08% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.82m | 0.87% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 1.64m | 0.78% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.41m | 0.68% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 1.41m | 0.67% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
